tetano
Editor, Senior Moderator
J Clin Virol. 2020 Apr 14;127:104371. doi: 10.1016/j.jcv.2020.104371. [Epub ahead of print]
Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis.
Hu Y[SUP]1[/SUP], Sun J[SUP]1[/SUP], Dai Z[SUP]1[/SUP], Deng H[SUP]1[/SUP], Li X[SUP]1[/SUP], Huang Q[SUP]1[/SUP], Wu Y[SUP]1[/SUP], Sun L[SUP]1[/SUP], Xu Y[SUP]2[/SUP].
Author information
Abstract
BACKGROUND:
Since being first reported in Wuhan, China, in December 8, 2019, the outbreak of the novel coronavirus, now known as COVID-19, has spread globally. Some case studies regarding the characteristics and outcome of patients with COVID-19 have been published recently. We conducted a meta-analysis to evaluate the risk factors of COVID-19.
METHODS:
Medline, SinoMed, EMBASE, and Cochrane Library were searched for clinical and epidemiological studies on confirmed cases of COVID-19.
RESULTS:
The incidence of fever, cough, fatigue, and dyspnea symptoms were 85.6 % (95CI 81.3-89.9 %), 65.7 % (95CI 60.1-71.4 %), 42.4 % (95CI 32.2-52.6 %) and 21.4 % (95CI 15.3-27.5 %). The prevalence of diabetes was 7.7 % (95CI 6.1-9.3 %), hypertension was 15.6 % (95CI 12.6-18.6 %), cardiovascular disease was 4.7 % (95CI 3.1-6.2 %), and malignancy was 1.2 % (95CI 0.5-1.8 %). The complications, including ARDS risk, ranged from 5.6-13.2 %, with the pooled estimate of ARDS risk at 9.4 %, ACI at 5.8 % (95CI 0.7-10.8 %), AKI at 2.1 % (95CI 0.6-3.7 %), and shock at 4.7 % (95CI 0.9-8.6 %). The risks of severity and mortality ranged from 12.6 to 23.5% and from 2.0 to 4.4 %, with pooled estimates at 18.0 and 3.2 %, respectively. The percentage of critical cases in diabetes and hypertension was 44.5 % (95CI 27.0-61.9 %) and 41.7 % (95CI 26.4-56.9 %), respectively.
CONCLUSION:
Fever is the most common symptom in patients with COVID-19. The most prevalent comorbidities are hypertension and diabetes which are associated with the severity of COVID-19. ARDS and ACI may be the main obstacles for patients to treatment recovery. The case severe rate and mortality is lower than that of SARS and MERS.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
COVID-19; Comorbidities; Mortality; Severity; Symptom
PMID:32315817DOI:10.1016/j.jcv.2020.104371
Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis.
Hu Y[SUP]1[/SUP], Sun J[SUP]1[/SUP], Dai Z[SUP]1[/SUP], Deng H[SUP]1[/SUP], Li X[SUP]1[/SUP], Huang Q[SUP]1[/SUP], Wu Y[SUP]1[/SUP], Sun L[SUP]1[/SUP], Xu Y[SUP]2[/SUP].
Author information
Abstract
BACKGROUND:
Since being first reported in Wuhan, China, in December 8, 2019, the outbreak of the novel coronavirus, now known as COVID-19, has spread globally. Some case studies regarding the characteristics and outcome of patients with COVID-19 have been published recently. We conducted a meta-analysis to evaluate the risk factors of COVID-19.
METHODS:
Medline, SinoMed, EMBASE, and Cochrane Library were searched for clinical and epidemiological studies on confirmed cases of COVID-19.
RESULTS:
The incidence of fever, cough, fatigue, and dyspnea symptoms were 85.6 % (95CI 81.3-89.9 %), 65.7 % (95CI 60.1-71.4 %), 42.4 % (95CI 32.2-52.6 %) and 21.4 % (95CI 15.3-27.5 %). The prevalence of diabetes was 7.7 % (95CI 6.1-9.3 %), hypertension was 15.6 % (95CI 12.6-18.6 %), cardiovascular disease was 4.7 % (95CI 3.1-6.2 %), and malignancy was 1.2 % (95CI 0.5-1.8 %). The complications, including ARDS risk, ranged from 5.6-13.2 %, with the pooled estimate of ARDS risk at 9.4 %, ACI at 5.8 % (95CI 0.7-10.8 %), AKI at 2.1 % (95CI 0.6-3.7 %), and shock at 4.7 % (95CI 0.9-8.6 %). The risks of severity and mortality ranged from 12.6 to 23.5% and from 2.0 to 4.4 %, with pooled estimates at 18.0 and 3.2 %, respectively. The percentage of critical cases in diabetes and hypertension was 44.5 % (95CI 27.0-61.9 %) and 41.7 % (95CI 26.4-56.9 %), respectively.
CONCLUSION:
Fever is the most common symptom in patients with COVID-19. The most prevalent comorbidities are hypertension and diabetes which are associated with the severity of COVID-19. ARDS and ACI may be the main obstacles for patients to treatment recovery. The case severe rate and mortality is lower than that of SARS and MERS.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
COVID-19; Comorbidities; Mortality; Severity; Symptom
PMID:32315817DOI:10.1016/j.jcv.2020.104371